CA2933556A1 - Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof - Google Patents
Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof Download PDFInfo
- Publication number
- CA2933556A1 CA2933556A1 CA2933556A CA2933556A CA2933556A1 CA 2933556 A1 CA2933556 A1 CA 2933556A1 CA 2933556 A CA2933556 A CA 2933556A CA 2933556 A CA2933556 A CA 2933556A CA 2933556 A1 CA2933556 A1 CA 2933556A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- compound
- alpha
- dihydroxy
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915575P | 2013-12-13 | 2013-12-13 | |
| US61/915,575 | 2013-12-13 | ||
| PCT/US2014/070156 WO2015089475A1 (en) | 2013-12-13 | 2014-12-12 | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2933556A1 true CA2933556A1 (en) | 2015-06-18 |
Family
ID=52282957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2933556A Abandoned CA2933556A1 (en) | 2013-12-13 | 2014-12-12 | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9353079B2 (https=) |
| EP (1) | EP3080096A1 (https=) |
| JP (2) | JP2016539994A (https=) |
| KR (1) | KR20160097310A (https=) |
| CN (1) | CN105814033B (https=) |
| AU (1) | AU2014361794B2 (https=) |
| BR (1) | BR112016013594A8 (https=) |
| CA (1) | CA2933556A1 (https=) |
| CL (2) | CL2016001448A1 (https=) |
| IL (2) | IL245917B (https=) |
| MX (1) | MX2016007717A (https=) |
| RU (1) | RU2730520C2 (https=) |
| SA (1) | SA516371307B1 (https=) |
| SG (2) | SG11201604787SA (https=) |
| UA (1) | UA121108C2 (https=) |
| WO (1) | WO2015089475A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2019023211A1 (en) | 2017-07-25 | 2019-01-31 | Allergan, Inc. | SOLID COMPLEX COMPRISING (Z) -7 - ((1R, 2R, 3R, 5S) -2 - ((S, E) -5- (2,5-DICHLOROTHIOPHEN-3-YL) -3-HYDROXYPENT-1 EN-1-YL) -3,5-DIHYDROXYCYCLOPENTYL) HEPT-5-ENAMIDE, PREPARATION THEREOF AND USES THEREOF |
| WO2021152473A1 (en) * | 2020-01-29 | 2021-08-05 | Kci Licensing, Inc. | Multiple fluid pathway connector with foam supports |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES416865A1 (es) * | 1972-07-13 | 1976-03-01 | Pfizer | Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15. |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US6602900B2 (en) * | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| WO1996036599A1 (en) * | 1995-05-18 | 1996-11-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
-
2014
- 2014-12-12 SG SG11201604787SA patent/SG11201604787SA/en unknown
- 2014-12-12 AU AU2014361794A patent/AU2014361794B2/en not_active Ceased
- 2014-12-12 JP JP2016538513A patent/JP2016539994A/ja active Pending
- 2014-12-12 CA CA2933556A patent/CA2933556A1/en not_active Abandoned
- 2014-12-12 US US14/569,210 patent/US9353079B2/en active Active
- 2014-12-12 CN CN201480067663.3A patent/CN105814033B/zh not_active Expired - Fee Related
- 2014-12-12 RU RU2016123446A patent/RU2730520C2/ru active
- 2014-12-12 BR BR112016013594A patent/BR112016013594A8/pt not_active IP Right Cessation
- 2014-12-12 EP EP14824284.5A patent/EP3080096A1/en not_active Withdrawn
- 2014-12-12 KR KR1020167018489A patent/KR20160097310A/ko not_active Ceased
- 2014-12-12 UA UAA201606260A patent/UA121108C2/uk unknown
- 2014-12-12 MX MX2016007717A patent/MX2016007717A/es unknown
- 2014-12-12 SG SG10201709702UA patent/SG10201709702UA/en unknown
- 2014-12-12 WO PCT/US2014/070156 patent/WO2015089475A1/en not_active Ceased
-
2016
- 2016-05-05 US US15/147,700 patent/US20170087163A1/en not_active Abandoned
- 2016-05-30 IL IL245917A patent/IL245917B/en active IP Right Grant
- 2016-06-10 CL CL2016001448A patent/CL2016001448A1/es unknown
- 2016-06-13 SA SA516371307A patent/SA516371307B1/ar unknown
-
2019
- 2019-02-22 CL CL2019000471A patent/CL2019000471A1/es unknown
- 2019-12-23 JP JP2019231685A patent/JP2020073513A/ja active Pending
-
2021
- 2021-06-08 IL IL283810A patent/IL283810A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9353079B2 (en) | 2016-05-31 |
| IL245917A0 (en) | 2016-08-02 |
| CL2016001448A1 (es) | 2017-03-03 |
| SG10201709702UA (en) | 2018-01-30 |
| WO2015089475A1 (en) | 2015-06-18 |
| RU2730520C2 (ru) | 2020-08-24 |
| US20170087163A1 (en) | 2017-03-30 |
| US20150166504A1 (en) | 2015-06-18 |
| SG11201604787SA (en) | 2016-07-28 |
| IL283810A (en) | 2021-07-29 |
| CN105814033A (zh) | 2016-07-27 |
| UA121108C2 (uk) | 2020-04-10 |
| JP2016539994A (ja) | 2016-12-22 |
| EP3080096A1 (en) | 2016-10-19 |
| CL2019000471A1 (es) | 2019-07-12 |
| SA516371307B1 (ar) | 2018-10-04 |
| AU2014361794B2 (en) | 2019-04-04 |
| CN105814033B (zh) | 2019-10-25 |
| JP2020073513A (ja) | 2020-05-14 |
| AU2014361794A1 (en) | 2016-06-16 |
| IL245917B (en) | 2021-06-30 |
| KR20160097310A (ko) | 2016-08-17 |
| MX2016007717A (es) | 2016-09-09 |
| BR112016013594A2 (https=) | 2017-08-08 |
| BR112016013594A8 (pt) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1072266B1 (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
| JP2017128605A (ja) | 抗ウイルス化合物の固体形態 | |
| JP2020073513A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| KR0162637B1 (ko) | 단백질 키나아제 c 억제제로서 유용한 신규 퀴놀릴옥사졸-2-온 | |
| CN102234287A (zh) | 硝基咪唑类化合物、其制备方法和用途 | |
| US12492192B2 (en) | Crystalline form of lifitegrast, and pharmaceutical composition comprising the same | |
| EP2528908B1 (en) | Therapeutic agents for treatment of ocular hypertension | |
| JP2005519117A (ja) | キノリン誘導体 | |
| TWI659041B (zh) | 類固醇樣化合物之多晶型形式以及其製備方法及用途 | |
| HK1227389A1 (en) | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof | |
| CN1225093A (zh) | 苯并[g]喹啉衍生物 | |
| JPH06102664B2 (ja) | 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての５―カルバモイルチエノ〔２，３―ｂ〕チオフエン―２―スルホンアミド類及び製造方法 | |
| HK1227410A1 (en) | Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof | |
| HK1227389B (zh) | α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法 | |
| JPWO2006082820A1 (ja) | 性器ヘルペス治療剤 | |
| HK1178524A (en) | Therapeutic agents for treatment of ocular hypertension | |
| HK1178524B (en) | Therapeutic agents for treatment of ocular hypertension | |
| HUP9902404A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230306 |